Product Description
Centanafadine is a triple monoamine inhibitor of norepinephrine (half-maximal inhibitory concentration [IC50] 6 nM), dopamine (IC50 38 nM), and serotonin (IC50 83 nM) transporter reuptake. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292254/)
Mechanisms of Action: SRI Inhibitor, NRI Inhibitor, DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Japan, Puerto Rico, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity|Phobia, Social
Phase 2: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05536414 |
JUNIPER | P2 |
Completed |
Depressive Disorder, Major |
2025-05-16 |
12% |
2025-05-31 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT05279313 |
NCT05279313 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2026-04-24 |
21% |
2026-05-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06973577 |
NCT06973577 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity|Phobia, Social |
2026-04-22 |
19% |
2026-05-07 |
Primary Endpoints|Treatments|Trial Status |
jRCT2071250004 |
jRCT2071250004 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-31 |
|||
NCT06926829 |
NCT06926829 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-01 |
29% |
2025-04-16 |
Primary Endpoints|Treatments |
NCT06931080 |
NCT06931080 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-01 |
24% |
2025-04-17 |
Primary Endpoints|Treatments |
jRCT2071250051 |
jRCT2071250051 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-08-31 |
|||
jRCT2071250045 |
jRCT2071250045 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-08-31 |
|||
NCT07087327 |
NCT07087327 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-08-01 |
23% |
2025-07-29 |
Primary Endpoints |
NCT07086313 |
NCT07086313 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-08-01 |
19% |
2025-07-26 |
Primary Endpoints|Treatments |
NCT07314333 |
NCT07314333 | P1 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2026-03-30 |
50% |
2026-05-06 |
|
NCT05428033 |
NCT05428033 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2025-03-17 |
9% |
2025-04-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07253441 |
NCT07253441 | P1 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2024-12-30 |
2025-12-12 |
||
jRCT2071250001 |
jRCT2071250001 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-31 |